4 June 2018 - - New York, New York- and Jerusalem, Israel-based clinical-stage pharmaceutical company Oramed Pharmaceuticals (NASDAQ: ORMP) (TASE: ORMP) has patented its invention, titled "Methods and Compositions for Oral Administrations of Proteins," with the United States Patent and Trademark Office (USPTO), the company said.
Oramed's protein oral delivery technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center.
The company completed multiple Phase II clinical trials of an orally ingestible insulin capsule under an investigational new drug application with the US Food and Drug Administration and are also developing an oral glucagon-like peptide-1 analog capsule.
Oramed Pharmaceuticals is focused on changing the field of diabetes care by advancing oral delivery solutions for drugs currently delivered via injection.